The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Trends in the prescription of opioids and gabapentinoids in patients with failed back surgery syndrome in Korea: a population-based study

  • Jinyoung Oh (Department of Anesthesiology and Pain Medicine, Kyungpook National University School of Medicine, Kyunpook National University Chilgok Hospital) ;
  • Jinseok Yeo (Department of Anesthesiology and Pain Medicine, Kyungpook National University School of Medicine, Kyunpook National University Chilgok Hospital)
  • Received : 2023.08.28
  • Accepted : 2023.12.06
  • Published : 2024.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Failed back surgery syndrome (FBSS) is a chronic condition that is characterized by persistent back pain following one or more spinal surgeries. Pharmacological interventions, such as the use of opioids and gabapentinoids, are frequently used in the treatment of FBSS. However, prolonged and excessive use of these medications can lead to dependence and adverse effects. This study investigates trends in opioid and gabapentinoid prescriptions among patients with FBSS in Korea from 2016 to 2020. Methods: Data from the Health Insurance and Review Agency were analyzed, and claims listing FBSS were selected for the study. Prescription patterns of opioids and gabapentinoids were classified based on the number of days prescribed per year. Results: Of the 390,095 patients diagnosed with FBSS, 41.6% of the patients were prescribed gabapentinoids, and 42.0% of them were prescribed opioids, while 10.6% of the patients were classified as long-term gabapentinoid users, 11.4% as long-term opioid users, and 7.4% of the patients were found to have long-term prescriptions for both drugs. The proportion of patients who received both gabapentinoid and opioid prescriptions increased annually. The doses of opioids prescribed have also increased along with the increase in the number of patients receiving opioid prescriptions. Conclusions: The prescription rates of opioids and gabapentinoids among patients with FBSS in Korea continue to increase steadily, posing potential risks of addiction and adverse effects. Further research is needed to better understand the actual status of addiction in patients with FBSS.

Keywords

Acknowledgement

The authors thank the HIRA for providing their dataset.

References

  1. Wu A, March L, Zheng X, Huang J, Wang X, Zhao J, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med 2020; 8: 299.
  2. Deyo RA, Gray DT, Kreuter W, Mirza S, Martin BI. United States trends in lumbar fusion surgery for degenerative conditions. Spine (Phila Pa 1976) 2005; 30: 1441-5. https://doi.org/10.1097/01.brs.0000166503.37969.8a
  3. National Health Insurance Service. 2020 Annual report of major surgery statistics [Internet]. National Health Insurance Service; 2021. Available at: https://www.nhis.or.kr/nhis/together/wbhaec06800m01.do?mode=view&articleNo=10813594
  4. Baber Z, Erdek MA. Failed back surgery syndrome: current perspectives. J Pain Res 2016; 9: 979-87. https://doi.org/10.2147/JPR.S92776
  5. Waguespack A, Schofferman J, Slosar P, Reynolds J. Etiology of long-term failures of lumbar spine surgery. Pain Med 2002; 3: 18-22. https://doi.org/10.1046/j.1526-4637.2002.02007.x
  6. Parker SL, Mendenhall SK, Godil SS, Sivasubramanian P, Cahill K, Ziewacz J, et al. Incidence of low back pain after lumbar discectomy for herniated disc and its effect on patient-reported outcomes. Clin Orthop Relat Res 2015; 473: 1988-99. https://doi.org/10.1007/s11999-015-4193-1
  7. Chen YC, Lee CY, Chen SJ. Narcotic addiction in failed back surgery syndrome. Cell Transplant 2019; 28: 239-47. https://doi.org/10.1177/0963689718796072
  8. Goodman CW, Brett AS. A clinical overview of offlabel use of gabapentinoid drugs. JAMA Intern Med 2019; 179: 695-701.
  9. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm 2019; 15: 953-8.
  10. Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008; 24: 521-7. Erratum in: Clin J Pain 2014; 30: 830.
  11. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001; 22: 672-87.
  12. Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17: 977-1007. https://doi.org/10.6004/jnccn.2019.0038
  13. Petersen EA, Schatman ME, Sayed D, Deer T. Persistent spinal pain syndrome: new terminology for a new era. J Pain Res 2021; 14: 1627-30. https://doi.org/10.2147/JPR.S320923
  14. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019; 160: 19-27. https://doi.org/10.1097/j.pain.0000000000001384
  15. Thomson S, Jacques L. Demographic characteristics of patients with severe neuropathic pain secondary to failed back surgery syndrome. Pain Pract 2009; 9: 206-15. https://doi.org/10.1111/j.1533-2500.2009.00276.x
  16. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect 2016; 4: e00205.
  17. Robertson K, Marshman LAG, Plummer D, Downs E. Effect of gabapentin vs pregabalin on pain intensity in adults with chronic sciatica: a randomized clinical trial. JAMA Neurol 2019; 76: 28-34. Erratum in: JAMA Neurol 2019; 76: 117.
  18. Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: review of the Canadian Pain Society consensus statement. Can Fam Physician 2017; 63: 844-52.
  19. Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018; 178: 292-4. https://doi.org/10.1001/jamainternmed.2017.7856
  20. Hudson TJ, Edlund MJ, Steffick DE, Tripathi SP, Sullivan MD. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manage 2008; 36: 280-8. https://doi.org/10.1016/j.jpainsymman.2007.10.003
  21. Sullivan MD, Von Korff M, Banta-Green C, Merrill JO, Saunders K. Problems and concerns of patients receiving chronic opioid therapy for chronic noncancer pain. Pain 2010; 149: 345-53. https://doi.org/10.1016/j.pain.2010.02.037
  22. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 2013; (8): CD004959.
  23. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018; 319: 872-82. https://doi.org/10.1001/jama.2018.0899
  24. Sullivan MD, Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008; 138: 440-9.
  25. Martin BI, Deyo RA, Mirza SK, Turner JA, Comstock BA, Hollingworth W, et al. Expenditures and health status among adults with back and neck problems. JAMA 2008; 299: 656-64. Erratum in: JAMA 2008; 299: 2630.
  26. Song IA, Choi HR, Oh TK. Long-term opioid use and mortality in patients with chronic non-cancer pain: ten-year follow-up study in South Korea from 2010 through 2019. EClinicalMedicine 2022; 51: 101558.
  27. Long DM, Filtzer DL, BenDebba M, Hendler NH. Clinical features of the failed-back syndrome. J Neurosurg 1988; 69: 61-71. https://doi.org/10.3171/jns.1988.69.1.0061
  28. Volkow ND, McLellan AT. Opioid abuse in chronic pain--misconceptions and mitigation strategies. N Engl J Med 2016; 374: 1253-63. https://doi.org/10.1056/NEJMra1507771
  29. Kobus AM, Smith DH, Morasco BJ, Johnson ES, Yang X, Petrik AF, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain 2012; 13: 1131-8.
  30. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85-92. https://doi.org/10.7326/0003-4819-152-2-201001190-00006
  31. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ 2017; 189: E659-66. https://doi.org/10.1503/cmaj.170363
  32. Hauser W, Bock F, Huppe M, Nothacker M, Norda H, Radbruch L, et al.; Koautoren fur die Konsensusgruppe der 2. Aktualisierung der S3-Leitlinie LONTS. [Recommendations of the second update of the LONTS guidelines: long-term opioid therapy for chronic noncancer pain]. Schmerz 2020; 34: 204-44. German. Erratum in: Schmerz 2021; 35: 59-60.
  33. Moisset X, Martinez V. Opioid use for the management of chronic non-cancer pain: French guidelines. Rev Neurol (Paris) 2016; 172: 337-8. https://doi.org/10.1016/j.neurol.2016.05.004
  34. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010; 66: 947-53. https://doi.org/10.1007/s00228-010-0853-y
  35. Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig 2017; 37: 763-73. https://doi.org/10.1007/s40261-017-0530-3
  36. Campbell LS, Coomer TN, Jacob GK, Lenz RJ. Gabapentin controlled substance status. J Am Pharm Assoc (2003) 2021; 61: e218-24. https://doi.org/10.1016/j.japh.2021.01.025
  37. Bao H, Wu Z, Wang Q, Wang J, Zhang L, Meng L, et al. The efficacy of gabapentin combined with opioids for neuropathic cancer pain: a meta-analysis. Transl Cancer Res 2021; 10: 637-44. https://doi.org/10.21037/tcr-20-2692
  38. Knezevic NN, Aijaz T, Camacho-Ortega A, Candido KD. A retrospective analysis of gabapentinoid and opioids to opioid monotherapy for pain relief in patients with chronic neck and low back pain. Pain Med 2021; 22: 1760-6.
  39. Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf 2018; 41: 213-28. https://doi.org/10.1007/s40264-017-0595-1
  40. Peet ED, Dana B, Sheng FY, Powell D, Shetty K, Stein BD. Trends in the concurrent prescription of opioids and gabapentin in the US, 2006 to 2018. JAMA Intern Med 2023; 183: 162-4.
  41. Hojsted J, Nielsen PR, Guldstrand SK, Frich L, Sjogren P. Classification and identification of opioid addiction in chronic pain patients. Eur J Pain 2010; 14: 1014-20. https://doi.org/10.1016/j.ejpain.2010.04.006
  42. O'Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain 2017; 21: 3-19. https://doi.org/10.1002/ejp.970
  43. Elkholy MAE, Nagaty A, Abdelbar AE, Simry HAM, Raslan AM. Effect of spinal cord stimulation on quality of life and opioid consumption in patients with failed back surgery syndrome. Pain Pract 2023. doi: 10.1111/papr.13300
  44. De La Porte C, Van de Keift E. Spinal cord stimulation in failed back surgery syndrome. Pain 1993; 52: 55-61. https://doi.org/10.1016/0304-3959(93)90113-4
  45. Van Buyten JP, Van Zundert J, Vueghs P, Vanduffel L. Efficacy of spinal cord stimulation: 10 years of experience in a pain centre in Belgium. Eur J Pain 2001; 5: 299-307. https://doi.org/10.1053/eujp.2001.0249
  46. de la Porte C, Siegfried J. Lumbosacral spinal fibrosis (spinal arachnoiditis). Its diagnosis and treatment by spinal cord stimulation. Spine (Phila Pa 1976) 1983; 8: 593-603. https://doi.org/10.1097/00007632-198309000-00005
  47. Ohnmeiss DD, Rashbaum RF, Bogdanffy GM. Prospective outcome evaluation of spinal cord stimulation in patients with intractable leg pain. Spine (Phila Pa 1976) 1996; 21: 1344-50. https://doi.org/10.1097/00007632-199606010-00013
  48. Nissen M, Ikaheimo TM, Huttunen J, Leinonen V, Jyrkkanen HK, von Und Zu Fraunberg M. Higher preimplantation opioid doses associated with longterm spinal cord stimulation failure in 211 patients with failed back surgery syndrome. Neuromodulation 2021; 24: 102-11. https://doi.org/10.1111/ner.13297
  49. Dhruva SS, Murillo J, Ameli O, Morin PE, Spencer DL, Redberg RF, et al. Long-term outcomes in use of opioids, nonpharmacologic pain interventions, and total costs of spinal cord stimulators compared with conventional medical therapy for chronic pain. JAMA Neurol 2023; 80: 18-29. https://doi.org/10.1001/jamaneurol.2022.4166
  50. Yousef AA, EL-Deen AS, Al-Deeb AE. The role of adding hyaluronidase to fluoroscopically guided caudal steroid and hypertonic saline injection in patients with failed back surgery syndrome: a prospective, double-blinded, randomized study. Pain Pract 2010; 10: 548-53.